Dr. med. Frank Himmel


Himmel F, Weil J, Reppel M, Mortensen K, Franzen K, Leidinger A, Schunkert H, Bode F: Improved heart rate dynamics in patients undergoing percutaneous renal denervation. J Clin Hypertens 14, 654-655 (2012).

Himmel F, Reppel M, Mortensen K, Schunkert H, Bode F: A strategy to achieve CRT response in permanent atrial fibrillation without obligatory atrioventricular node ablation. Pacing Clin Electrophysiol 35, 943-947 (2012).

Himmel F, Bode F, et al. Successful single-sided renal denervation approach in a patient with stenosis of an accessory renal artery. J Clin Hypertens 14, 187-188 (2012).

Bode F, Himmel F, Reppel M, Mortensen K, Schunkert H, Wiegand UK: Should all dysfunctional high-voltage leads be extracted? Results of a single-centre long-term registry. Europace 14, 1764-1770 (2012).

Mortensen K, Franzen K, Himmel F, Bode F, Schunkert H, Weil J, Reppel M: Catheter-based renal sympathetic denervation improves central hemodynamics and arterial stiffness: a pilot study. J Clin Hypertens 14, 861-870 (2012).

Himmel F, Bode F, Schunkert H, Weil J: Die renale Denervation als neue Behandlungsmöglichkeit der therapierefraktären arteriellen Hypertonie.
Praxis 2, 1353-1360 (2011).

Mahfoud F, Himmel F, Ukena C, Schunkert H, Böhm M, Weil J: Behandlungsstrategien bei therapierefraktärer arterieller Hypertonie. Dtsch Arztebl Int. 108, 725-731 (2011).
geteilte Erstautorenschaft

Himmel F, Bode F, Mortensen K, Graf T, Schunkert H, Weil J: Die renale Denervation als Therapiestrategie der medikamentös refraktären arteriellen Hypertonie. Nieren- und Hochdruckkrankheiten 40, 111-116 (2011)

Ihr Herz - mein Fokus
Dr. med Himmel

Himmel F, Hunold P, Schunkert H, Bode F: Influenza A positive but H1N1 negative myocarditis in a patient coming from a high outbreak region of new influenza. Cardiol J 18,441-445 (2011).

Burgdorf C, Hänsel L, Heidbreder M, Jöhren O, Schütte F, Schunkert H, Kurz T: Suppression of cardiac phosphatidate phosphohydrolase 1 activity and lipin mRNA expression in Zucker diabetic fatty rats and humans with type 2 diabetes mellitus. Biochem Biophys Res Commun 390, 165-170 (2009)

Bode F, Schütte F: [Optimized CRT programming: Relevance and practical application.]. Herzschrittmacherther Elektrophysiol 30,121-130

Schütte F, Lüdorff G, Grove R, Kranig W, Thale J: Atrioventricular node ablation is not a prerequisite for cardiac resynchronisation therapy in patients with chronic atrial fibrillation. Cardiol J 16, 246-249 (2009)

Schütte F, Ebstein M, Rottmann M, Thale J: Nearly asymptomatic left ventricular apical ballooning after a hit-and-run accident. Int J Cardiol 128, 439-441 (2008)

Schütte F, Burgdorf C, Richardt G, Kurz T: Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Can J Physiol Pharmacol 84, 573-577 (2006)

Burgdorf C, Richardt G, Schütte F, Dendorfer A, Kurz T: Impairment of presynaptic α2-adrenoceptor-regulated norepinephrine overflow in failing hearts from Zucker diabetic fatty rats. J Cardiovasc Pharmcol 47, 256-262 (2006)

Burgdorf C, Schütte F, Kurz T, Dendorfer A, Richardt G: Adenylyl cyclase-dependent inhibition of myocardial norepinephrine release by
presynaptic adenosine A1-receptors. J Cardiovasc Pharmacol 45, 1-3 (2005)

Burgdorf C, Dendorfer A, Kurz T, Schömig E, Stölting I, Schütte F, Richardt G: Role of Neuronal KATP Channels and Extraneuronal Monoamine Transporter on Norepinephrine Overflow in a Model of Myocardial Low Flow Ischemia. J Pharmacol Exp Ther 309, 42-48 (2004)